This study aims to describe in detail the patient journey from diagnosis to the beginning of treatment and patterns of care of hormone receptor- positive, HER2-negative de novo or recurrent metastatic breast cancer between January 2018 and December 2020 in Brazil.

Inclusion Criteria:

• Women ≥18 years old
• Histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer
• Hormone receptor-positive defined as 1% to 100% of tumor nuclei positive for Estrogen - - Receptor and/or Progesterone Receptor, as per ASCO/CAP Guideline 2020 - or Allred score of ≥3
• HER2-negative defined as IHC result is 0/1+ or 2+ with ISH negative as per ASCO/CAP Guideline 2018
• Diagnosed with de novo or recurrent metastatic breast cancer between January 2018 -and December 2020
• Public health system or private health system

Exclusion Criteria:

• Male Breast Cancer
• First-line treatment for mBC received through clinical trial

Women histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer

The study will be performed in up to 15 sites in Brazil so that the recruitment target is reached within defined milestones. An adequate geographical distribution of sites within Brazil will be pursued to strengthen representation of Brazilian population. Considering the incidence of mBC.